Alfuzosin versus tamsulosin for symptomatic benign prostatic hyperplasia: a prospective comparative study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20262863Keywords:
Alfuzosin, Benign prostatic hyperplasia, IPSS, Lower urinary tract symptoms, Tamsulosin, UroflowmetryAbstract
Background: Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in aging men. Alpha-1 adrenergic receptor antagonists are recommended as first-line pharmacological therapy. This study compared the efficacy and safety of alfuzosin and tamsulosin in men with symptomatic BPH.
Methods: In this prospective, open-label, comparative study, 60 men with symptomatic BPH were allocated to receive either alfuzosin 10 mg once daily (n=30) or tamsulosin 0.4 mg once daily (n=30) for 12 weeks. International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), and post-void residual urine volume (PVRU) were assessed at baseline, 4 weeks, and 12 weeks. Adverse events were recorded throughout the study.
Results: Baseline characteristics were comparable between groups. Both treatments produced significant improvement in IPSS, Qmax, and PVRU from baseline to 12 weeks (all p<0.001). At 12 weeks, mean IPSS was lower in the alfuzosin group than in the tamsulosin group (6.30±2.02 vs. 7.37±2.17; p=0.050). Mean Qmax increased from 6.03±1.81 to 23.33±3.79 ml/s with alfuzosin and from 6.30±1.73 to 21.60±4.10 ml/s with tamsulosin (p=0.090). Mean PVRU decreased from 85.30±28.51 to 11.40±6.08 ml and from 73.90±45.51 to 14.83±11.93 ml, respectively (p=0.160). Both medications were well tolerated, and no serious adverse events occurred.
Conclusions: Both alfuzosin and tamsulosin significantly improved LUTS, urinary flow rate, and bladder emptying in men with symptomatic BPH. Their efficacy and safety profiles were broadly comparable.
References
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-9.
Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6(Suppl 9):S3-10.
Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3-14.
Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147(Suppl 2):S88-119.
Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15(3):193-9.
Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2023. J Urol. 2024;211(1):11-19.
Manjunatha R, Pundarikaksha HP, Madhusudhana HR, Amarkumar J, Hanumantharaju BK. A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia. Indian J Pharmacol. 2016;48(2):134-40.
Buzelin JM, Fonteyne E, Kontturi M, Witjes WP. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Brit J Urol. 1997;80(4):597-605.
Karadağ E, Öner S, Budak YU, Atahan Ö. Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. Int Urol Nephrol. 2011;43(4):949-54.
Fusco F, Palmieri A, Ficarra V, et al. Alpha-1 adrenergic antagonists for benign prostatic hyperplasia: A systematic review and meta-analysis. BJU Int. 2016;118(5):673-83.
Mari A, Antonelli A, Tubaro A, et al. Efficacy and safety of alfuzosin in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: Systematic review and meta-analysis. Urol. 2021;153:1-10.
Parsons JK, Dahm P, Köhler TS, Lerner LB. Benign prostatic hyperplasia and male lower urinary tract symptoms: A review. JAMA. 2024;331(4):345-56.
Halawani A, Paterson R, Zhong T, Du K, Ren R, Forbes CM. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate Res Innov. 2024;12(2):57-64.
Cornu JN, Baboudjian M, Netsch C, Hashim H, Creta M, Pyrgidis N, et al. Management of non-neurogenic male lower urinary tract symptoms: Better holistic than sequential. Eur Urol. 2025;88(3):223-7.
McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-release alfuzosin and its effect on symptoms and quality of life in patients with benign prostatic hyperplasia. Eur Urol. 2001;39(4):427-35.
Downloads
Published
How to Cite
Issue
Section
